Feature Article: The Next Generation of Cell Factories for Viral Vector Production

The true potential of gene therapy – with the incredible promise to treat a vast variety of diseases – will only be realised through enhanced manufacturing practices. In a recent article published in Genetic Engineering and Biotechnology News, the technologies, approaches and tools needed to standardize viral vector production and ensure the pipeline meets GMP …

Read more Feature Article: The Next Generation of Cell Factories for Viral Vector Production

Selecting the right cell line development technology: data-driven solutions for setting up or enhancing a CLD lab

When establishing or updating a cell line development (CLD) lab, we all look to minimize short terms effects on productivity and to reap new efficiencies as soon as possible. Physical installation time, establishing new workflow validation and even optimizing media and supplements are all factors that can influence the efficiency and economic viability of introducing …

Read more Selecting the right cell line development technology: data-driven solutions for setting up or enhancing a CLD lab

Redefining cell line development

Following the launch of Solentim’s new ICON™ instrument and dedicated STUDIUS™ software, the two of which complete the company’s cutting-edge ecosystem, we spoke with Dr Ian Taylor, Chief Business Officer, Solentim, to find out what this means for cell line development and the future of antibody therapeutics.

Read more Redefining cell line development

Why Evercell Bio chose VIPS: a new workflow for hiPSC in cell therapy

Philip D. Manos, Founder and President of EverCell Bio, Natick, Massachusetts, USA “Our mission is to accelerate the implementation of human and disease-specific stem cell technologies for drug discovery and personalized medicine” EverCell Bio is a single-source provider of customized services for the application of stem cell technology in cell therapy. EverCell offers human cell-modelling …

Read more Why Evercell Bio chose VIPS: a new workflow for hiPSC in cell therapy

Solentim Appoints New Non-Executive Director

Solentim are pleased to announce the appointment of Dr Julian Burke as a non-executive Director. A former lecturer in Biochemistry at the University of Sussex, UK, Dr Burke has over 25 years’ experience of executive leadership positions in life science companies. He was Chief Scientific Officer for Genetix Group PLC from 2000 – 2010 until …

Read more Solentim Appoints New Non-Executive Director